IASO Biotherapeutics (IASO Bio), a clinical-stage biopharmaceutical company, announced that the Office of Orphan Products Development (OOPD) of the U.S. Food and Drug Administration (FDA) has granted the Orphan Drug Designation (ODD) to the company
Found this useful? Share it with your team.
